Willing to perform at least two methods of contraception
Willing to use contraception throughout the study period.
Willing to use adequate contraception for the duration of time on the study and for  months after the last therapy
Willing to use adequate contraception while on the study and until  days after the last dose of study drug
Willing to use adequate contraception while on the study and until  days after the last dose of study drug
Willing to use adequate contraception throughout the study and for  weeks after study drug discontinuation
Men and women must be willing to use appropriate contraception throughout study and for  months after
Willing to use contraception when appropriate
Willing to use effective contraception for at least -days post study drug administration.
Must be willing to implement contraception throughout study and for  days after receiving the study drug.
Must be willing to implement contraception throughout study and for the  weeks following last viral administration
Contraception.
Women of childbearing potential must be willing to implement adequate contraception during the study. An adequate method of contraception will be at the investigator's discretion.
Men must be willing to use appropriate contraception throughout study and for  months after; women must be willing to use appropriate contraception throughout study and for  months after
Must be willing to use contraception during the study, and for  days following the last dose of study drug
Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for  days following the last dose of MM-
Must be willing to implement contraception throughout study and for the  weeks following last study drug administration.
Men not willing to use an effective contraception method while on study
Not willing to use contraception (inclusive of abstinence)
Is the subject willing to use condoms for contraception for  months after receiving Toca  or until there is no evidence of the virus in his/her blood, whichever is longer. If the subject is a fertile female, is she willing to use contraception for at least  months?
Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for  days following the last dose of MM-
Pregnant and lactating females, and unwillingness to use contraception; or male subject not willing to use contraception during and for  days after the last dose of pazopanib therapy
Willing to use adequate contraception to avoid pregnancy or impregnation until  weeks after discontinuing study agent
Willingness to use adequate contraception to avoid pregnancy or impregnation until  weeks after discontinuing study agent
Willing to continue on the same or similar type of contraception during the  month course of study; if using non-hormonal contraception, continue that and if hormonal contraception continue that; if heterosexually active, must be agreeable to use some form of contraception during the trial unless husband or partner has had a vasectomy or subject has had uterus removed; safety of SDG during pregnancy has not been documented
Use of adequate contraception during the study
TREATMENT GROUP: Willing to avoid oral contraception use (which is not recommended while on tamoxifen treatment) for the duration of the study participation
Willing to use contraception during and for  month after completion of the study
Willing to abstain from procreative sex or partake in appropriate form of contraception; for the purpose of this study, condom use or abstinence will be required
Willing to use adequate contraception if applicable, and to continue use for  weeks post last dose of GSK
